GlaxoSmithKline takes case against Pfizer over meningococcal vaccine - (The Irish Times via NewsPoints Desk)

  • GlaxoSmithKline has filed a lawsuit in Ireland accusing Pfizer of infringing patents for its meningococcal vaccine Bexsero, The Irish Times reported.

  • A spokeswoman for Pfizer, which markets the meningococcal vaccine Trumenba, said the company will be "vigorously" defending itself against the litigation.

  • Revenue for Bexsero doubled in the third quarter to 133 million pounds, while GlaxoSmithKline has struggled to keep pace with the surging demand for the vaccine.

  • Meanwhile, Pfizer previously received FDA approval for Trumenba for preventing invasive meningococcal disease caused by Neisseria meningitidis serogroup B in 2014, while the drugmaker is seeking to expand the use of the vaccine globally.

  • FirstWord Reports: Providing insight, analysis and expert opinion on important Pharma trends and challenging issues <Click here>

To read more NewsPoints articles, click here.

Reference Articles